Cholinergic Drugs-ppp

Cholinergic Drugs-ppp - Dr ug MOA Comment Effect...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Dr ug MOA Comment Effect Characteristics Side Effe cts Nm Agonist & Nn agonist Non-Selective Ni co tin e Drug of Abuse Stim. of Symp ganglia ( HR, CNS effect~ dopamine release (relaxation)) Nm Antagonist Competitive Agents D- Tu bo cu rar in e Occupy Ach sites on NmR, no efficacy Transmembrane potential: -80mV Uses: Paralysis & relaxation of SKM allows for lower doses of general anesthetic Reduce SE (like cardio & resp. depression), shortened recovery time . Paralysis of pharyngeal & laryngeal muscles for endotracheal intubation , paralysis of resp. muscles in intubated patients w/ ventilatory failure Flaccid Paralysis (of sk.m) Long duration of action-Blocks Nn Receptors- Release of histamine from mast cells-Analogs clinically used bc fewer side effects & better PK profile Depolarizing Agents Su cci ny lch oli ne Occupy Ach binding sites on NmR-55 mV (persistent inactivation of voltage- gated Na+ channels) Transient Fasciculations followed by flaccid paralysis (of sk.m) Rapid onset, Short duration of action (rapid metabolism by BuChE, duration of action in patients w/ BuChE deficiency~...
View Full Document

Page1 / 7

Cholinergic Drugs-ppp - Dr ug MOA Comment Effect...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online